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Abstract
Background and purpose Low-grade glioma (LGG) is a
very common brain tumor in pediatric patients typically as-
sociated with a very good prognosis. This prognosis makes
it imperative that the risk of long-term treatment-related
side effects be kept at an absolute minimum. Proton therapy
(PRT) provides a radiation technique that has the potential
to further reduce the genesis of radiogenic impairment.
Materials and methods We retrospectively assessed 74 pa-
tients with LGG who underwent PRT. Conventional three-
dimensional photon and PRT plans were generated after
contouring structures of neurogenesis, crucial neuronal
structures, and areas susceptible to secondary malignan-
cies. Target volume coverage was evaluated using the
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homogeneity index (HI) and inhomogeneity coefficient
(IC). Results were compared using the Wilcoxon-signed
rank test, with p < 0.05 being statistically significant.
Results Target volume coverage was comparable for the
photon and proton plans. Overall, we could show an es-
sential reduction in maximal, mean, and integral doses in
critical neurologic structures, areas of neurogenesis, and
structures of neurocognitive function. The study indicated
specifically how contralaterally located structures could be
spared with PRT.
Conclusion PRT is a highly conformal radiation technique
offering superior dosimetric advantages over conventional
radiotherapy by allowing significant dose reduction for or-
gans at risk (OAR) that are essential for neurologic func-
tion, neurocognition, and quality of life, thus demonstrating
the potential of this technique for minimizing long-term se-
quelae.
Keywords Brain tumors · Children · Neurogenesis ·
Quality of life · Organs at risk
Dosimetrische Vorteile der Protonentherapie
gegenüber der konventionellen Strahlentherapie
mit Photonen bei jungen Patienten und
Erwachsenen mit niedriggradigem Gliom
Zusammenfassung
Hintergrund und Ziel Niedriggradige Gliome (LGG) zäh-
len zu den häufigsten Hirntumoren im Kindesalter und sind
üblicherweise mit einer sehr guten Prognose vergesellschaf-
tet. Es gilt daher, das Risiko für therapieassoziierte Spätfol-
gen so gering wie möglich zu halten. Mit der Protonenbe-
strahlung steht eine Bestrahlungsmodalität zur Verfügung,
mit der das Auftreten radiogener Spätfolgen im Vergleich
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zu konventionellen Bestrahlungstechniken weiter minimiert
werden könnte.
Material und Methoden Für diese Studie wurden 74 kon-
sekutive Patienten retrospektiv ausgewertet, die aufgrund
eines LGG einer Protonenbestrahlung unterzogen wurden.
Ergänzend wurden zunächst auf der Planungscomputerto-
mographie die für neurokognitive Funktionen relevanten
Zentren sowie Strukturen der Neurogenese identifiziert und
konturiert; anschließend wurden korrelierende konventio-
nelle Photonenpläne berechnet. Die Zielvolumenabdeckung
wurde mithilfe des Homogenitätsindex (HI) und des Inho-
mogenitätskoeffizienten (IC) beurteilt und die Ergebnisse
mit dem Wilcoxon-Vorzeichen-Rang-Test verglichen, wo-
bei ein p-Wert < 0,05 als statistisch signifikant gewertet
wurde.
Ergebnisse Die Zielvolumenabdeckung war sowohl für
Photonen- als auch für Protonenpläne vergleichbar. Insge-
samt konnte mit der Protonentherapie nicht nur die Inte-
graldosis des gesunden Gehirngewebes, sondern auch die
maximale und mittlere Dosisbelastung der zuvor definier-
ten kritischen Risikoorgane deutlich gesenkt werden. Dies
gilt in besonderem Maße für die dem Tumor kontralateral
gelegene Hemisphäre.
Schlussfolgerung Die Protonenbestrahlung zeigt eine der
konventionellen Radiotherapie mit Photonen in Hinblick
auf Risikoorganschonung bei weitem überlegene dosimetri-
sche Verteilung, mit dem großen Potential, radiogene Spät-
folgen – wie die Beeinträchtigung neurologischer und neu-
rokognitiver Funktionen und der Lebensqualität – zu mini-
mieren.
Schlüsselwörter Hirntumor · Kinder · Neurogenese ·
Lebensqualität · Risikoorgane
Low-grade gliomas (LGG) are the most common type of
brain tumor in children. Today, the prognosis is very good
and pediatric patients are expected to become long-term
survivors. It is, therefore, essential to reduce the risk of
long-term side effects as much as possible.
Surgery is generally accepted as the first-line treatment
if a complete resection can be achieved without major neu-
rologic impairment. However, in many cases, only a partial
resection or biopsy can be performed due to an unfavor-
able localization in proximity to vital structures such as the
brainstem, optic system, pituitary, hypothalamus, or other
areas of the brain with critical functions. Since the risk for
disease progression is significantly higher in cases of subto-
tal compared to complete resection [1], radiotherapy plays
an important role in the treatment of pediatric LGG. Radio-
therapy is one of the most effective treatment alternatives,
achieving high long-term control rates [2, 3]; although its
use is not undisputed. Nevertheless, given the good prog-
nosis, particular attention is paid to reduction of potential
treatment-related sequelae. Younger patient age has been
attributed with a higher risk of neurocognitive impairment,
neurologic deficits, reduced quality of life, and secondary
malignancies. The recommended lower age limit for initia-
tion of radiotherapy differs among international protocols:
European trials set the threshold at 8 years of age [4], while
North American studies advise waiting until the age of 10
[5]. However, adult patients also show a tendency to de-
velop dementia more frequently after cranial irradiation [6],
which is known to be related to a significant impairment of
the patient’s quality of life.
Over time, many technical advances, such as three-di-
mensional (3D) treatment planning, image guidance, inten-
sity modulation, and particle therapy, have been adopted
in daily routine, leading to incremental improvements in
terms of conformity. Three-dimensional conformal radio-
therapy (3D-CRT) is a widely available radiation technique
accepted as standard [7–9]. A multitude of data is available
for 3D-CRT, but long-term studies of PRT are still scarce.
Along with the commissioning of new proton facilities, the
use of PRT is rapidly increasing [10]. Due to its distinct
biophysical properties with typically low doses in the beam
entrance area and a nearly complete dose deposition in the
so-called Bragg-peak, PRT is a highly conformal technique
that allows steep dose gradients. As a result, excellent
target coverage can be maintained without compromises
due to nearby critical OAR because their tolerances are not
exceeded. In view of the dosimetric superiority of PRT
compared to 3D-CRT, this study was conducted to present
in detail the influence on structures that are essential for
neurocognitive function, in addition to specific OAR that
are responsible for neurologic side effects or impairment of
quality of life. In the world of radiation oncology, sparing
of the hippocampus and other stem cell niches has become
a topic of particular interest [11, 12]. However, there are
several risk factors for the development of neurocognitive
dysfunction: in addition to radiotherapy, tumor localiza-
tion, the extent of resection, and concomitant chemother-
apy are recognized risk factors [13]. The authors set out to
determine and quantify the superiority of PRT in terms of
dose distribution for the abovementioned OAR and, thereby,




A total of 74 patients with histologically proven LGG
originally treated at the authors’ institution between 2012
and 2014 were retrospectively selected for this comparative
study. All patients presented with supratentorial or infraten-
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torial disease. Approximately half of the patients (n = 36;
48.6 %) were children or young adults under 30 years of
age (Table 1). For treatment planning, patients were fixed
using custom-made mask fixation and underwent prethera-
peutic computed tomography (CT) and magnetic resonance
imaging (MRI). All patients underwent 3D-PRT or inten-
sity-modulated proton therapy (IMPT) with a median dose
of 54 Gy (range 50.4–60 Gy) in 1.8 Gy per fraction (range
1.8–2.0 Gy), with a horizontal beamline using the raster
scanning technique [14]. The patient collective encom-
passed a wide range of histological LGG subgroups among
pilocytic astrocytoma (n = 28; 37.8 %), fibrillary astro-
cytoma (n = 22; 29.7 %), and oligodendroglioma (n = 6;
8.1 %). Median age of patients with pilocytic astrocytoma
was 16.2 years (2.0–53.3 years) and this was 36.3 years
(5.9–64.2 years) for other LGG.
Contouring and treatment planning
Contouring was performed on the patients’ original treat-
ment planning CT scans and fused with the pretherapeutic
MRI using contrast-enhanced T2 fluid-attenuated inversion
recovery (FLAIR) imaging. The initial gross tumor volume
(GTV) was defined as the hyperintense low-grade tumor
mass, surgical resection cavity, and perifocal edema on T2-
FLAIR. A safety margin of up to 1 cm was added for the
clinical target volume (CTV) to account for microscopic
spread. All OAR were contoured using coregistered T1-
weighted postcontrast MRI on axial views. In the authors’
study group, at the time of initial treatment planning and
delivery, the additional OAR were not explicitly contoured,
monitored, or used as avoidance structures for either treat-
ment technique. Contouring of the initial and additional
OAR and the treatment volume definition for photon and
particle therapy planning was performed using the Siemens
Dosimetrist and Oncologist software (Siemens, Erlangen,
Germany). Photon RT and PRT re-planning were performed
on the original planning CT datasets and dose recalculation
was done using the initial planning parameters. Further-
more, additional crucial cerebral structures for neurogene-
sis, secondary malignancies, and neuronal functions were
contoured retrospectively. To allocate the laterality, we de-
termined the tumor key area regardless of bilateral tumor
growth. Ipsilateral (IL) and contralateral (CL) subventricu-
lar zones (SVZ) were contoured as a 5-mm margin lateral
to the lateral ventricles as previously described [15, 16].
The hippocampus and amygdala were contoured according
to previously published guidelines [17]. The hypothala-
mus and thalamus were contoured in accordance with pre-
viously published contouring landmarks [18, 19]. Brain
structures were contoured including supraentorial and in-
fratentorial brain areas. The brainstem comprised the mid-
brain, pons, and medulla oblongata. The pituitary gland,
Table 1 Patient characteristics




Median age in years (range) 31.2 (2.0–64.2)
Surgical resection 43 (58.1)
Gross total resection 11 (14.9)
Subtotal resection 31 (41.9)
Resection status unclear 2 (2.7)
Biopsy 30 (40.5)
Median PTV volume in ml (range) 185.2 (11.8–709.6)
Median total dose in Gy (range) 54.0 (50.4–60)
Median single dose in Gy (range) 1.8 (1.8–2.0)
PTV planning target volume
cochlear IL and CL, optic nerves, and chiasm were identi-
fied and contoured following previously published recom-
mendations [20]. Treatment planning was performed by
a single experienced radiation therapist using the Oncen-
tra MasterPlan® (Nucletron, Columbia, SC, USA) planning
system, version 4.5, with a collapsed cone algorithm for
3D photon treatment planning. In 3D-CRT, beam directions
were carefully selected and consisted of four to five copla-
nar and non-coplanar fields in the majority of cases and, if
necessary, subfields, using a field-in-field (FIF) technique.
For all patients, 6-MV photons were used. Treatment plan-
ning for proton therapy was performed using the treatment
planning system Syngo PT Planning (Siemens). For the
plan comparison, ion beams were applied using a horizontal
beam or the gantry. Two to three coplanar or non-coplanar
beams were used for the particle therapy treatment. The
gantry rotation was not restricted in the coplanar and non-
coplanar settings. The pencil beams chosen for the PRT
typically had a lateral full width at half maximum (FWHM)
of 10 mm. The treatment table position was restricted to
between 10 and 170 degrees to avoid collisions of the hori-
zontal beam nozzle with the table. To assure comparability,
the same target volumes and OAR were used for particle
and photon plans. Tolerance levels for the OAR were based
on the work of QUANTEC [21–25]. Planning target vol-
ume (PTV) coverage of ≥ 95 % of the prescribed dose was
required and in all patients, at the time of treatment plan-
ning and delivery, the additional OAR were monitored but
not considered an avoidance structure in either radiotherapy
modality.
Treatment plan evaluation
Qualitative and quantitative dose evaluations were con-
ducted for both radiotherapy modalities. Dose–volume
histograms (DVHs) were constructed for all volumes, and
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dose parameters were extracted to check for proper target
volume coverage and to assure compliance with the OAR
dose constraints. PTV coverage was assessed utilizing
measurement of the volume receiving ≥ 90 %, ≥ 95 %, and
≥ 100 % of the prescribed relative doses (in %). Confirma-
tion of PTV dose distribution was evaluated by calculating
HI and IC.




Inhomogeneity coe f f icient (IC) =
Dmax −Dmin
Dmean
D5 and D95 are the minimum doses in 5 % and 95 % of
the PTV, respectively, and Dp is the prescribed dose in the
PTV. The ideal HI value is zero, where D5 equals D95 [26].
The IC assesses the distribution variance of the PTV dose,
where higher values indicate greater variability [27]. Dmax
and Dmin represent the maximum and minimum doses in the
PTV, respectively, and Dmean equals the average PTV dose.
Integral dose (ID) = ∑
i
Dmean×Vi
The integral dose (ID) is defined as the sum of the mean
dose multiplied by the volume if the voxels are assumed
to be the same size and the organ is hypothesized to have
a uniform density. The ID also represents the area under the
DVH curve at all dose levels [28] and allows evaluation of
the lower dose spread compared to conventional measure-
ments. Dmean equals the average dose of the target volume
or OAR, and Vi is defined as the structure volume in ml.
The simplified formula was used in this analysis: Dmean ×
volume.
Table 2 Comparison of target volume coverage
3D-CRT PRT p-value
V90 % (in %) 96.10 ± 3.56 97.54 ± 3.26 0.238
V95 % (in %) 94.62 ± 5.95 96.36 ± 5.26 0.361
V100 % (in %) 85.12 ± 12.08 85.75 ± 9.35 0.751
Dmax (in %) 105.81 ± 2.82 106.56 ± 2.45 0.324
Dmean (in %) 99.66 ± 1.89 99.78 ± 1.39 0.979
Dmin (in %) 85.23 ± 12.08 84.90 ± 12.21 0.969
HI (in %) 8.85 ± 5.62 5.84 ± 5.42 0.001*
IC (in %) 0.21 ± 0.13 0.22 ± 0.13 0.694
Values are given as mean values with standard deviations
*Indicates a statistically significant p-value
3D-CRT three-dimensional conventional radiotherapy, PRT proton beam therapy, V90 % percentage of planning target volume (PTV) that receives
a minimum of 90 % of the prescribed dose, V95 % percentage of PTV that receives a minimum of 95 % of the prescribed dose, V100 % percentage of
PTV that receives a minimum of 100 % of the prescribed dose, Dmax maximum dose to the PTV, Dmean average dose to the PTV, Dmin minimum
dose to the PTV, HI homogeneity index: (D5 %–D95 %)/prescribed dose × 100, IC inhomogeneity coefficient: (Dmax–Dmin)/Dmean
Data management and automatic dose–volume analysis
All PRT data and additional treatment information were
available in the central research database of the authors’
department, which functioned as the central data source
like previously described [29]. Project-specific OAR
re-contouring and 3D-CRT data were additionally im-
ported into the central research database after re-planning.
Dose–volume analysis was performed automatically on
a central analysis platform directly connected to the central
research database like previously described [30]. A work-
flow was designed to analyze the radiotherapeutic imaging
data (RT data) of all patients with the abovementioned re-
contouring. First, RT data was retrieved from the central
research database and preprocessed for analysis. During
analysis, dose statistics and DVHs were calculated auto-
matically. All results were written into the central storage
of the analysis platform. Finally, results for all patients
were summarized in a single result file for further statistical
analysis.
Ethics
The study was approved by the Ethics Committee, Univer-
sity of Heidelberg (no. S-056/2015).
Statistical analysis
Statistical analysis was carried out with SigmaPlot™ (Sy-
stat Software GmbH, Erkrath, Germany) software. The
Wilcoxon signed-rank test was applied for analysis with
corresponding two-sided 95 % confidence intervals. A p-
value < 0.05 was considered statistically significant.
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Fig. 1 Cumulative dose–volume histogram DVH (n = 74) compar-
ing planning target coverage for both proton beam therapy (PRT) and
three-dimensional conventional radiotherapy (3D-CRT)
Table 3 Dose comparison of organs at risk
Organ at risk 3D-CRT
(relative dose in % ± SD)
PRT




Optic nerve ipsilateral Dmax 64.4 ± 35.5 56.2 ± 39.0 –12.8 0.165
Dmean 38.4 ± 28.3 33.0 ± 28.5 –14.0 <0.001*
Mean ID 62.8 ± 61.0 54.7 ± 59.5 –12.9 0.480
Optic nerve contralateral Dmax 56.5 ± 33.9 36.4 ± 36.7 –35.6 <0.001*
Dmean 26.4 ± 22.0 14.8 ± 20.1 –44.0 <0.001*
Mean ID 43.2 ± 43.7 25.6 ± 44.7 –40.7 0.008*
Inner ear ipsilateral Dmax 56.8 ± 33.4 44.5 ± 37.6 –21.6 0.015*
Dmean 43.4 ± 29.5 26.3 ± 26.9 –39.3 <0.001*
Mean ID 61.6 ± 43.1 38.1 ± 41.4 –38.1 <0.001*
Inner ear contralateral Dmax 34.6 ± 23.1 12.5 ± 22.8 –63.7 <0.001*
Dmean 24.9 ± 18.8 7.2 ± 15.3 –71.0 <0.001*
Mean ID 35.7 ± 31.1 9.2 ± 19.7 –74.1 <0.001*
Optic chiasm Dmax 76.6 ± 28.8 66.8 ± 35.7 –12.7 0.033*
Dmean 63.5 ± 29.8 44.5 ± 33.8 –30.0 <0.001*
Mean ID 146.1 ± 96.4 109.2 ± 103.2 –25.2 0.017*
Thalamus ipsilateral Dmax 82.4 ± 27.0 83.5 ± 26.6 1.3 0.059
Dmean 66.7 ± 31.3 58.8 ± 32.8 –11.9 <0.001*
Mean ID 498.0 ± 266.1 433.1 ± 270.5 –13.0 0.025*
Thalamus contralateral Dmax 76.2 ± 27.9 69.3 ± 35.2 –9.0 0.598
Dmean 54.5 ± 27.7 32.9 ± 29.1 –39.7 <0.001*
Mean ID 419.4 ± 241.6 260.5 ± 243.9 –37.9 <0.001*
SVZ ipsilateral Dmax 88.9 ± 19.0 86.3 ± 22.1 –3.0 0.301
Dmean 57.9 ± 30.8 50.5 ± 31.2 –12.9 <0.001*
Mean ID 765.5 ± 552.4 731.9 ± 639.9 –4.4 0.069
Results
PTV coverage
Target volume coverage was comparable in both treatment
modalities. No statistically significant difference could be
detected regarding V90 % and V95 % (percentage of PTV re-
ceiving a minimum of 90 and 95 % of the prescribed dose,
respectively). Similar findings for values can be identified
by comparing the HI and IC (Table 2). Although not sig-
nificant, when comparing the cumulative DVH for PTV,
slightly better target coverage as well as a lower maximum
dose for protons can be observed (Fig. 1).
Sparing organs at risk
Critical organs of the central nervous system
Dose-limiting OAR with limiting tolerance doses and re-
gions at risk of secondary malignancies were assessed to
compare both treatment modalities (Table 3 and Fig. 4).
PRT allowed for significant sparing of critical IL and CL
auditory organs. Here, the Dmax and ID doses were decreas-
ed by 21.6 and 38.1 % IL, and 63.7 and 74.1 % CL, re-
spectively. Similar results were seen for the optical system,
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Table 3 Dose comparison of organs at risk (Continued)
Organ at risk 3D-CRT
(relative dose in % ± SD)
PRT




SVZ contralateral Dmax 75.5 ± 23.7 61.4 ± 36.0 –18.7 0.006*
Dmean 38.2 ± 21.9 16.8 ± 18.7 –56.1 <0.001*
Mean ID 531.7 ± 342.4 246.9 ± 350.6 –53.6 <0.001*
Hypothalamus Dmax 78.9 ± 27.1 72.5 ± 35.4 –8.2 0.494
Dmean 67.6 ± 29.6 50.4 ± 35.2 –25.5 <0.001*
Mean ID 192.9 ± 107.2 144.2 ± 117.2 –25.2 <0.001*
Hippocampus ipsilateral Dmax 84.6 ± 22.0 80.0 ± 29.5 –5.5 0.610
Dmean 64.0 ± 30.5 54.2 ± 35.9 –15.3 <0.001*
Mean ID 391.7 ± 207.8 327.2 ± 229.8 –16.5 0.060
Hippocampus contralateral Dmax 64.7 ± 24.7 40.6 ± 39.2 –37.2 <0.001*
Dmean 39.1 ± 21.6 13.9 ± 21.6 –64.5 <0.001*
Mean ID 248.6 ± 149.8 92.8 ± 156.7 –62.7 <0.001*
Amygdala ipsilateral Dmax 77.0 ± 29.3 70.0 ± 36.5 –9.2 0.128
Dmean 69.1 ± 32.3 59.9 ± 38.1 –13.3 <0.001*
Mean ID 52.0 ± 39.5 48.0 ± 47.8 –7.7 0.075
Amygdala contralateral Dmax 60.4 ± 30.0 39.2 ± 41.0 –35.0 <0.001*
Dmean 49.5 ± 28.5 26.6 ± 34.0 –46.3 <0.001*
Mean ID 41.0 ± 35.5 25.4 ± 41.9 –37.9 <0.001*
Lateral ventricle ipsilateral Dmax 89.1 ± 18.6 88.0 ± 20.8 –1.3 0.841
Dmean 59.0 ± 30.2 50.0 ± 29.5 –15.2 <0.001*
Mean ID 1085.9 ± 1306.3 976.6 ± 1009.1 –10.1 0.035*
Lateral ventricle contralateral Dmax 81.3 ± 22.4 75.9 ± 30.0 –6.7 0.315
Dmean 45.6 ± 24.9 25.0 ± 22.9 –45.3 <0.001*
Mean ID 896.3 ± 833.3 511.3 ± 687.4 –42.9 <0.001*
Supratentorial Dmax 103.4 ± 10.4 103.7 ± 12.8 +0.3 0.386
Dmean 37.8 ± 19.6 24.5 ± 14.8 –35.2 <0.001*
Mean ID 45154.0 ± 24207.3 29958.7 ± 19079.9 –33.7 <0.001*
Infratentrorial Dmax 90.5 ± 25.7 88.1 ± 32.8 –2.7 0.447
Dmean 33.5 ± 18.7 14.3 ± 19.0 –57.5 <0.001*
Mean ID 7388.1 ± 6400.3 3818.6 ± 10575.3 –48.3 <0.001*
Pituitary gland Dmax 65.3 ± 33.8 49.2 ± 38.2 –24.6 0.003*
Dmean 57.8 ± 33.4 34.1 ± 35.1 –40.9 <0.001*
Mean ID 34.7 ± 27.4 21.6 ± 25.8 –37.8 <0.001*
Brain stem Dmax 86.4 ± 16.7 79.4 ± 27.5 –8.2 0.153
Dmean 51.7 ± 23.1 28.1 ± 26.3 –45.6 <0.001*
Mean ID 1467.4 ± 947.2 775.9 ± 761.2 –47.1 <0.001*
Brain Dmax 105.8 ± 2.9 106.4 ± 3.1 +0.6 0.447
Dmean 37.2 ± 17.2 23.1 ± 12.3 –38.0 <0.001*
Mean ID 52898.6 ± 24823.9 33100.1 ± 18828.2 –37.4 <0.001*
*Indicates a statistically significant p-value.
3D-CRT three-dimensional conventional radiotherapy, PRT proton beam therapy, Dmax maximum dose to the planning target volume (PTV),
Dmean average dose to the PTV, Dmin minimum dose to the PTV, ID integral dose, SVZ subventricular zone, SD standard deviation
where the dose to the optic nerve (ON) CL and optic chi-
asm were decreased by 35.6 % (Dmax), 44.0 % (Dmean), and
40.7 % (ID); and 12.7 % (Dmax), 30.0 % (Dmean), and 25.2 %
(ID), respectively. Findings for the IL ON did not reach
statistical significance. PRT reduced the Dmax and ID to
the centrally located pituitary gland by 24.6 and 37.8 %,
respectively. Normal brain tissue, as a potential risk area
for secondary malignancies, could be spared significantly.
Here, the ID to supratentorial and infratentorial brain areas
could be reduced by 33.7 and 48.3 %, respectively (each
< 0.001). Similar decreases in Dmean (45.6 and 38.0 %) and
ID (47.1 and 37.4 %) followed for the brainstem and whole
brain, respectively (each <0.001). Cumulative DVHs are
shown in Figs. 2 and 3.
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Fig. 2 Cumulative dose–volume histograms for contralateral organs at risk showing a significant dose reduction for proton beam therapy com-
pared to three-dimensional conventional radiotherapy. SVZ subventricular zone
Critical organs of neurogenesis
It has been shown that neuronal stem cells—initiating cells
for neurogenesis even in adult individuals—are extremely
sensitive [31] and show diverse recovery behaviors after
exposure to ionizing radiation [32]. Sparing of the IL SVZ
was only significant for Dmean (–12.9 %). However, Dmax and
ID of the CL SVZ could be reduced by 18.7 % (<0.001)
and 53.6 % (<0.001), respectively, using PRT. The second
anatomic region that has been shown to harbor neuronal
stem cells is the dentate gyrus in the hippocampal forma-
tion. For the CL hippocampus, doses could be reduced by
Dmax: 37.2 %, Dmean: 64.5 %, and ID: 62.7 % (each <0.001).
For the IL hippocampus, only the Dmean to the hippocam-
pus could be decreased significantly at 15.3 % by applying
a PRT plan (< 0.001).
Critical structures of neurocognitive functions
Dmax (35.0 %), Dmean (46.3 %), and ID (37.9 %) to the CL
amygdala could be spared using proton plans. Analogous to
other IL structures, the IL amygdala had reductions of Dmean
by only 13.3 % (<0.001). Again, sparing of the CL thalamus
was superior to sparing of the IL thalamus when using PRT
plans. Relative decreases of Dmean: 39.7 % and ID: 37.9 %
(each <0.001) in the CL thalamus and Dmean: 13.0 % and
ID: 11.9 % (p = 0.025 and p < 0.001, respectively) in the
IL thalamus could be achieved.
Pilocytic astrocytoma versus other LGG
When assigning the patient collective further into pilocytic
astrocytoma (n = 28) and other LGG (n = 46), the latter
could be spared more effectively with PRT than the for-
mer. In detail, in the CL hippocampus (Dmax: –97.6 %
vs. –60.5 %, Dmean: –79.2 % vs. –3.0 %, ID: –97.8 %
vs. –61.1 %), CL amygdala (Dmax: –96.2 % vs. –33.3 %,
ID: –95.6 % vs. –36.7 %), brainstem (Dmax: –77.2 % vs.
–23.9 %, ID: –76.7 % vs. –23.3 %), pituitary gland (Dmean:
–45.5 % vs. –3.6 %, ID: –70.5 % vs. –12.6 %) and optic
chiasm (Dmax: –37.5 % vs. –16.6 %), the dose reduction
with PRT was more pronounced for non-pilocytic astro-
cytoma. Only in the IL hippocampus (Dmax: +4.5 % vs.
–20.8 %) and IL inner ear (Dmean: –6.6 % vs. –27.3 %) did
PRT decrease the dose in a more pronounced manner in
pilocytic astrocytoma.
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Fig. 3 Cumulative dose–volume histograms for unifocal organs at risk showing a significant dose reduction for proton beam therapy compared
to three-dimensional conventional radiotherapy
Discussion
These data present an overwhelming dosimetric advantage
of PRT over 3D-CRT in terms of sparing not only stem cell
niches, but also nearly any other OAR. In addition to the
significant reduction of mean dose and the ID bilaterally,
particularly on the CL side, the maximum dose could be
lowered. PRT offers distinct biophysical advantages over
conventional 3D-CRT. However, to what extent this will
have a clinical impact remains to be proven by long-term
observations. Particular attention must be paid to structures
that are considered essential for neurocognitive functions,
such as the hippocampus or the SVZ.
There are several reports of treatment planning compar-
isons for various entities. Boehling et al., for example, in-
vestigated the dose distribution in 10 representative cases of
pediatric craniopharyngioma for nearby critical structures
when using PRT instead of intensity modulated radiother-
apy with photons. Their study showed a reduction of the ID
received by the hippocampus of up to 51 % and up to 57 %
for the SVZ [33], whereby intensity modulated PRT had the
largest potential for relative dose reduction. Another study
published by Fuss et al. performed a dosimetric comparison
for optic pathway glioma focusing on the saving potential
for the CL ON, showing that PRT has the potential to nearly
halve the dose received (–47 %) [34]. A decrease in ID was
also noted for the chiasm (–11 %) and the pituitary (–13 %).
Likewise, dosimetric superiority for the whole brain, tem-
poral lobes, chiasm, and cochlea could be demonstrated in
both supratentorial and infratentorial locations [10, 35, 36].
The ID represents a valuable option for considering OAR
volumes in the dosimetric assessment. Here the ID should
offer objective values, which allow for improved evaluation
of lower dose spreads compared to Dmean or median dose.
However, even the ID is not able to predict normal tox-
icity complication probability (NTCP) without correlation
of clinical long-term toxicity data. All of these reports are
in accordance with the presented findings that there is no
difference between photon and proton plans with regard to
target coverage, all the more, however, for the CL OAR,
particularly when using intensity modulated PRT instead of
3D-PRT.
It is well known that the risk of occurrence and the sever-
ity of radiation-related impairment of neurocognitive func-
tion are correlated with both the dose and the irradiated vol-
ume of critical structures, such as the supratentorial brain
in general, or the hippocampus in particular. Especially in
children, a decrease in intelligence quotient (IQ), process-
ing speed, and fine motor skills has been reported [37–39].
Our particular focus was on the exposure of structures con-
K
Strahlenther Onkol (2016) 192:759–769 767
Fig. 4 Comparison of dose distribution for a patient with low grade
glioma. a Three-dimensional conventional radiotherapy plan, b pro-
ton beam therapy plan. CTV is delineated in red, the corresponding
planning target volume in blue. The potential for dose reduction is
especially eminent at the contralateral site
sidered crucial for neurocognitive performance, such as the
hippocampus, SVZ, amygdala, and thalamus. In contrast
to a general assessment of dose distribution (whole brain,
supratentorial, infratentorial, temporal lobe), a more de-
tailed analysis substantiated by clinical parameters could
lead to a better understanding and risk assessment for the
occurrence of neurocognitive impairment. Merchant et al.
showed that the dose reduction achieved by PRT has the
potential to mitigate neurocognitive impairment. The au-
thors collected dosimetric information for 40 patients with
different types of childhood brain tumors and calculated
the estimated decline in their full scale IQs using dose-
dependent cognitive effect models [40]. The reason for ra-
diation-induced neurocognitive impairment is most likely
multifactorial [13, 39]; however, there is growing evidence
that supports the idea that neural progenitor cells (NPCs) in
stem cell niches play an important role. The hippocampus
and the SVZ are known areas of origin for NPCs [11, 12].
Although their role has not yet been fully elucidated, it is
hypothesized that their capability for self-renewal and in-
jury repair is of central importance to the genesis of long-
term neurocognitive effects [41, 42]. To counteract a ra-
diogenic impairment of their recovery potential, every ef-
fort should be made to decrease the dose received by the
NPCs. While there is substantiated data for the correlation
between dose and hippocampus, the role of the SVZ is dis-
puted more vigorously [43]. One of the reasons is attributed
to its potential to contribute to tumor propagation [44].
As the current findings show, inter alia, PRT is an ex-
cellent treatment option that does not compromise target
coverage. Furthermore, these data underline that sparing
of cerebral OAR is more pronounced in the group of LGG
compared to pilocytic astrocytoma, which arise mainly from
midline structures. Here, PRT allows for improved spar-
ing of centrally localized neuronal structures like the hip-
pocampus, optic chiasm, brainstem, and pituitary gland.
Preliminary results from the prospective Radiation Ther-
apy Oncology Group (RTOG 0933) described the effect
of hippocampal sparing during whole brain irradiation and
concluded that decreased short-term memory impairment
compared to historical controls is attributed to sparing of
stem cell niches [45]. Whether, and how, these preliminary
results will be reflected in a clinically relevant decrease of
treatment-related long-term toxicity remains to be seen and,
of course, substantiated by long-term results.
Although the present findings provide strong evidence in
favor of PRT, their limitations should be considered. First,
following the recommendation of the German Society of
Radiation Oncology (DEGRO), PRT should be used sub-
ject to disease, localization and availability of patients with
LGG, as they are particularly appropriate candidates. LGG
is the most common diagnosis of central nervous system
malignancy in pediatric patients and the use of radiother-
apy must inevitably be considered, especially in patients
presenting with an unfavorable or irresectable tumor loca-
tion. In keeping with that recommendation, this study was
performed retrospectively. Second, the analysis compared
photons to protons in general, and this does not demonstrate
the full potential of each technique. A more detailed evalu-
ation of the role of intensity modulation for both photons
and protons is planned as the next step. Equally interest-
ing would be the possibility of taking the sensitive OAR
into consideration for treatment planning initially and also
consideration of whether there is an additional potential for
sparing OAR with protons, as is well-known from earlier
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planning studies with photons based on the motto that “see-
ing is saving.”
The strength of this study is its large number of patients
with proven LGG. To our knowledge, this is the largest
case series of LGG patients, providing valuable dosimetric
information because of its homogenous distribution to all
lobes of the brain. To minimize interobserver variability,
all OAR and all treatment plans were contoured/performed
by the same experienced radiation oncologist. In addition,
automated analysis of treatment-related data using a central
research database and the task-customized workflow min-
imized potential transmission or inadvertent errors. The
information obtained by the presented analysis is not only
helpful for identifying patients who would potentially bene-
fit from PRT, but also provides important arguments in in-
terdisciplinary discussions about why the effort should be
made to expand access to PRT.
However, as previously stated, the availability of proton
centers remains limited. This is why the authors’ goal is to
acquire new data and correlate dosimetric information with
functional outcomes, potentially providing further selection
criteria for patients who would benefit significantly from
PRT.
Conclusion
The dose distribution of PRT is significantly superior when
compared to conventional radiotherapy, particularly with
regard to OAR that are considered essential for neurologic
function and neurocognition, or which play an important
role in terms of quality of life. PRT might hereby lead to
reduced treatment-related side effects.
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